pyrazinamide has been researched along with Hepatitis B Virus Infection in 4 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 7.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| "To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide." | 3.73 | Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. ( Choi, MS; Chung, MP; Kim, H; Koh, WJ; Kwon, OJ; Lee, BH; Suh, GY, 2005) |
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 3.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stout, JE | 1 |
| Engemann, JJ | 1 |
| Cheng, AC | 1 |
| Fortenberry, ER | 1 |
| Hamilton, CD | 1 |
| Lee, BH | 1 |
| Koh, WJ | 1 |
| Choi, MS | 1 |
| Suh, GY | 1 |
| Chung, MP | 1 |
| Kim, H | 1 |
| Kwon, OJ | 1 |
| Valencia Ortega, ME | 1 |
| Türktaş, H | 1 |
| Unsal, M | 1 |
| Tülek, N | 1 |
| Orüç, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for pyrazinamide and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Topics: Adolescent; Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chemical an | 2003 |
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Topics: Adult; Antitubercular Agents; Carrier State; Case-Control Studies; Chemical and Drug Induced Liver I | 2005 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; D | 1994 |